Selenium and the course of mild Graves' orbitopathy

Area of Science:

• Ophthalmology
• Endocrinology
• Clinical Research

Background:

• Graves' orbitopathy pathogenesis involves oxygen free radicals and cytokines.
• Mild Graves' orbitopathy requires effective treatment to improve patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of selenium (antioxidant) and pentoxifylline (anti-inflammatory) in patients with mild Graves' orbitopathy.
• To compare the effects of selenium and pentoxifylline against a placebo over a 6-month treatment period and a subsequent 6-month follow-up.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 159 patients with mild Graves' orbitopathy.
• Patients received oral selenium (200 μg/day), pentoxifylline (1200 mg/day), or placebo for 6 months.
• Outcomes assessed included ophthalmic assessment, quality-of-life questionnaire, Clinical Activity Score, and diplopia score.

Main Results:

• Selenium treatment significantly improved quality of life (P<0.001) and reduced ocular involvement (P=0.01) compared to placebo.
• Selenium slowed the progression of Graves' orbitopathy (P=0.01) with a greater decrease in Clinical Activity Score.
• Pentoxifylline did not show significant benefits over placebo, and was associated with gastrointestinal side effects; selenium had no adverse events.

Conclusions:

• Selenium administration is effective in improving quality of life and reducing ocular manifestations in mild Graves' orbitopathy.
• Selenium offers a safe and effective therapeutic strategy for managing mild Graves' orbitopathy, slowing disease progression.
• Pentoxifylline was not found to be beneficial and presented tolerability issues in this patient cohort.